These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24066937)

  • 1. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat.
    Vavrinec P; Henning RH; Landheer SW; Wang Y; Deelman LE; Dokkum RP; Buikema H
    Curr Vasc Pharmacol; 2014; 12(6):836-44. PubMed ID: 24066937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
    Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
    J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity.
    Wang Y; Landheer S; van Gilst WH; van Amerongen A; Hammes HP; Henning RH; Deelman LE; Buikema H
    PLoS One; 2012; 7(10):e46781. PubMed ID: 23071636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vildagliptin in clinical practice: a review of literature.
    Banerjee M; Younis N; Soran H
    Expert Opin Pharmacother; 2009 Nov; 10(16):2745-57. PubMed ID: 19874253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
    Miyagawa K; Kondo T; Goto R; Matsuyama R; Ono K; Kitano S; Kawasaki S; Igata M; Kawashima J; Matsumura T; Motoshima H; Araki E
    Cardiovasc Diabetol; 2013 Nov; 12():160. PubMed ID: 24188631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
    Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
    Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.
    Matsui T; Nishino Y; Takeuchi M; Yamagishi S
    Pharmacol Res; 2011 May; 63(5):383-8. PubMed ID: 21320599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
    Sharma AK; Kanawat DS; Mishra A; Dhakad PK; Sharma P; Srivastava V; Joshi S; Joshi M; Raikwar SK; Kurmi MK; Srinivasan BP
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
    Ito H; Wajima T; Yamaguchi M; Mimori N; Sekiguchi K
    Nihon Yakurigaku Zasshi; 2010 Nov; 136(5):299-308. PubMed ID: 21079371
    [No Abstract]   [Full Text] [Related]  

  • 11. Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.
    Marques AP; Cunha-Santos J; Leal H; Sousa-Ferreira L; Pereira de Almeida L; Cavadas C; Rosmaninho-Salgado J
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):403-413. PubMed ID: 29154902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
    Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
    Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S; Sole S
    Eur J Pharm Sci; 2012 Sep; 47(2):456-63. PubMed ID: 22800967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.
    Eom YS; Gwon AR; Kwak KM; Kim JY; Yu SH; Lee S; Kim YS; Park IB; Kim KW; Lee K; Kim BJ
    PLoS One; 2016; 11(12):e0168569. PubMed ID: 27997588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats.
    Giani JF; Burghi V; Veiras LC; Tomat A; Muñoz MC; Cao G; Turyn D; Toblli JE; Dominici FP
    Am J Physiol Renal Physiol; 2012 Jun; 302(12):F1606-15. PubMed ID: 22492942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.
    Maeda S; Yamagishi S; Matsui T; Nakashima S; Ojima A; Maeda S; Nishino Y; Ishibashi Y; Yoshida Y; Yamakawa R
    Ophthalmic Res; 2013; 50(4):221-6. PubMed ID: 24081217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
    Akarte AS; Srinivasan BP; Gandhi S
    Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
    Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
    J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.
    Foley JE; Jordan J
    Vasc Health Risk Manag; 2010 Aug; 6():541-8. PubMed ID: 20730070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
    Apaijai N; Pintana H; Chattipakorn SC; Chattipakorn N
    Br J Pharmacol; 2013 Jul; 169(5):1048-57. PubMed ID: 23488656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.